PMID- 31633491
OWN - NLM
STAT- MEDLINE
DCOM- 20210827
LR  - 20210827
IS  - 1533-4058 (Electronic)
IS  - 1533-4058 (Linking)
VI  - 28
IP  - 10
DP  - 2020 Nov/Dec
TI  - Steroid Receptor Coactivator-1 Expression in Pheochromocytoma: Clinicopathologic 
      Correlation and Potential Diagnostic Pitfall.
PG  - 761-766
LID - 10.1097/PAI.0000000000000815 [doi]
AB  - Pheochromocytoma is a relatively uncommon tumor, and the histomorphologic and 
      biochemical features that may portend malignant behavior have poor overall 
      consensus across various proposed classification systems. Steroid receptor 
      coactivator-1 (SRC-1) is a nuclear protein that mediates transcriptional 
      activity. Current diagnostic applications of SRC-1 are limited, and include 
      distinguishing adrenocortical carcinoma (ACC) from renal cell carcinoma, and 
      other mimickers. SRC-1 expression in pheochromocytoma has not been previously 
      studied. Pheochromocytoma cases were retrieved from our Urological Pathology 
      database and expert consultation files of the senior author, from 2015 to 2019. 
      Clinicopathological data were obtained. SRC-1 expression was scored 
      systematically. Thirty-eight cases were included, with a female predominance, and 
      a mean age of 52 years (range, 16 to 75 y). Seven patients had heritable 
      mutations including RET (n=3), VHL (2), SDHB (1), and ATM and PDGFRA (1). Two 
      patients developed clinical metastasis, who individually had ATM and PDGFRA 
      mutations, and SDHB p.V140F mutation. All heritable tumors were positive for 
      SRC-1, including diffuse/strong staining and intensity in the VHL cases, and 
      diffuse staining with variable intensity in RET cases. Diffuse positivity was 
      seen in most of our heritable cases, providing evidence for a putative link 
      between RET and downstream SRC-1 signaling. An inverse relationship was observed 
      between SRC-1 expression and Pheochromocytoma of the Adrenal Gland Scaled 
      Score/tumor size, suggesting that SRC-1 phenotype may become muted in 
      pheochromocytomas that have malignant potential. SRC-1 expression in aggressive 
      pheochromocytomas, may also be a potential diagnostic pitfall in view of the fact 
      that these tumors may be misinterpreted as ACC in the primary or metastatic 
      setting.
FAU - Xiong, Meng-Jun
AU  - Xiong MJ
AD  - Departments of Pathology.
FAU - Osunkoya, Adeboye O
AU  - Osunkoya AO
AD  - Departments of Pathology.
AD  - Urology, Emory University School of Medicine.
AD  - Winship Cancer Institute of Emory University, Atlanta.
AD  - Department of Pathology, Veterans Affairs Medical Center, Decatur, GA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Appl Immunohistochem Mol Morphol
JT  - Applied immunohistochemistry & molecular morphology : AIMM
JID - 100888796
RN  - EC 2.3.1.48 (NCOA1 protein, human)
RN  - EC 2.3.1.48 (Nuclear Receptor Coactivator 1)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-ret)
RN  - EC 2.7.10.1 (RET protein, human)
SB  - IM
MH  - Adolescent
MH  - Adrenal Gland Neoplasms/diagnosis/*metabolism
MH  - Adrenocortical Carcinoma/*diagnosis
MH  - Adult
MH  - Aged
MH  - Diagnosis, Differential
MH  - Diagnostic Errors
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mutation/genetics
MH  - Neoplasm Metastasis
MH  - Nuclear Receptor Coactivator 1/*metabolism
MH  - Pheochromocytoma/diagnosis/*metabolism
MH  - Proto-Oncogene Proteins c-ret/genetics
MH  - Young Adult
EDAT- 2019/10/22 06:00
MHDA- 2021/08/28 06:00
CRDT- 2019/10/22 06:00
PHST- 2019/10/22 06:00 [pubmed]
PHST- 2021/08/28 06:00 [medline]
PHST- 2019/10/22 06:00 [entrez]
AID - 00129039-202011000-00006 [pii]
AID - 10.1097/PAI.0000000000000815 [doi]
PST - ppublish
SO  - Appl Immunohistochem Mol Morphol. 2020 Nov/Dec;28(10):761-766. doi: 
      10.1097/PAI.0000000000000815.